Imagine a smart, injectable jelly that fills deep wounds and heals itself if it breaks. It acts like a timed-release capsule, slowly delivering medicine to kill bacteria and regrow skin. This helps the body repair deep cavities that usually refuse to heal on their own.
Deep cavity chronic wounds are difficult to treat due to poor reachability, infection, and slow vascularization. This creates a massive economic burden, consuming up to 4% of EU healthcare spending.
A multifunctional, green 4D injectable self-healing hydrogel platform. It includes embedded immune-stealth microcapsules for the controlled delivery of antibacterial and pro-angiogenic agents.
If you are a drug delivery developer dealing with sensitive agents that degrade too quickly — this project developed immune-stealth microcapsules that protect these agents from enzymes. This ensures precise, sustained delivery of therapeutics directly into the wound site.
If you are a medical device manufacturer dealing with the difficulty of treating deep cavity wounds — this project developed a 4D injectable hydrogel. It provides a scalable matrix that supports cell adhesion and migration to accelerate tissue regeneration.
If you are a biotech company dealing with the need for sustainable, green medical materials — this project developed a platform based on functionalized pectin and gelatin. This creates a bioresorbable solution that is viable for industrial exploitation.
Based on available project data, specific pricing is not provided, but the project aims to address chronic wounds that currently account for 2-4% of EU healthcare costs.
Yes, the project objective explicitly includes scale-up production and the development of formulations viable for industrial exploitation.
Based on available project data, specific licensing terms are not listed, but the project involves business planning and consultation with regulatory agencies to prepare for industrial use.
The project runs from 2025-05-01 to 2028-04-30, aiming to be ready for first-in-man clinical trials immediately following the project's conclusion.
The solution is an injectable hydrogel, designed to be easily administered into deep cavity wounds to provide infection control and tissue regeneration.
The consortium is well-balanced for commercialization, consisting of 13 partners across 7 countries. With a 23% industry ratio (3 industrial partners, including 3 SMEs), there is a clear bridge between the 7 universities and 2 research institutes and the eventual market application.
Contact the Universita Degli Studi Del Piemonte Orientale Amedeo Avogadro in Italy.
Contact SciTransfer to explore licensing opportunities for this 4D hydrogel platform.
